Oil prices fell more than 5% in a sudden move on Tuesday after report said Saudi Arabia's oil production will restore to normal levels faster than initially expected.Marketsread more
Damage to the top OPEC producer's oil facilities ignited fears of supply disruption around the world and has sent crude prices soaring.Energyread more
The second-largest investor in Kraft Heinz Company discloses that it has again trimmed its stake in the food company.Marketsread more
Elliott Management may not see John Stankey as a future leader at AT&T, but bailing on him before he executes his integration plan has the potential for disaster.Technologyread more
Retailers could be in for a jolly jump in holiday sales despite headwinds like the U.S.-China trade war and threat of another economic slowdown.Retailread more
After two years working on Amazon's Rekognition technology, Humphrey Chen left to become product chief at VidMob and put the software into action.Technologyread more
Walmart likely discriminated against dozens of female workers in its stores, according to a Tuesday report from the Wall Street Journal.Retailread more
Canaccord Genuity's Tony Dwyer says Americans are spending less than ever on their fuel needs.Trading Nationread more
U.S. manufacturing output increased more than expected in August, boosted by a surge in machinery and primary metals production.Economyread more
After a series of setbacks on the road to an initial public offering, the parent company of real estate start-up WeWork is delaying the move, sources told CNBC Monday.Technologyread more
The service will debut in April with pricing to be announced closer to the launch data, NBCUniversal says.Technologyread more
A pharmacy warned the Food and Drug Administration that it found a chemical believed to cause cancer in a widely used blood pressure medication, according to a filing from the federal agency.
Valisure, an online pharmacy company licensed in 37 states, told the FDA last week that high levels of dimethylformamide were found in valsartan, a drug produced by Swiss drugmaker Novartis and other pharmaceutical companies. The drug is used to treat hypertension in adults. The World Health Organization classifies dimethylformamide, or DMF, as a probable human carcinogen.
Valisure asked that the medication be recalled and requested that the FDA review and significantly lower the acceptable intake of DMF from its current level of 8,800,000 nanograms to less than 1,000 nanograms. The online pharmacy said it found the cancer-causing chemical in valsartan produced by five companies.
The FDA will evaluate Valisure's findings and will respond directly to the online pharmacy firm, FDA spokesman Jeremy Kahn said in a statement to CNBC. Patients should continue to take their blood pressure medication even if it is recalled until their doctor provides a replacement or alternative treatment, he added. Abruptly discontinuing a medication is risky, he said.
In a statement to CNBC, a spokesperson for Novartis said in general the company's manufacturing process does not use DMF but it cannot currently fully "exclude the possibility that traces of DMF (within applicable limits) may have been present in materials of other Drug Substances suppliers."
"The quality and safety of all our products is of the utmost importance to Novartis," the spokesperson added.
Several blood pressure drugs have already been recalled due to concerns about other cancer-causing chemicals. Earlier this month, Israel-based Teva Pharmaceuticals said it would expand a recall of its heart medication, losartan potassium, after a carcinogen known asN-Nitrosodimethylamine, or NMBA was detected. Torrent Pharmaceuticals in April said it would also recall losartan and Camber Pharmaceutical told the FDA in February it would recall the drug.